Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Adapalene and Benzoyl Peroxide Gel, 0.1% 2.5%, the generic version of Epiduo Gel, 0.1% 2.5%, of Galderma Laboratories LP.
According to IQVIA sales data for the 12 month period ending September 2019, the Epiduo Gel, 0.1% 2.5% market achieved annual sales of approximately $33.7 million.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
